The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC
Open Access
- 2 June 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (4) , 771-788
Abstract
Background and Aims: Many patients with HCC present inadequate responses to lenvatinib therapy. Therefore, it is important to elucidate the underlying mechanisms of resistance and to formulate effective reversal strategies. Approach and Results: We conducted transcriptome and proteome sequencing analyses of lenvatinib-resistant cell lines and patient-derived tissues, identifying microtubule-associated serine/threonine kinase-like (MASTL) as a critical factor associated with lenvatinib resistance in HCC. Then, we utilized subcutaneous mouse models, half maximal inhibitory concentration (IC 50 ) measurements, and colony formation assays to determine the biological function of MASTL in promoting tumor growth and mediating resistance to lenvatinib. To further elucidate the underlying mechanisms, we performed co-immunoprecipitation and mass spectrometry analyses, revealing that MASTL facilitates the phosphorylation of Y-box binding protein-1 (YBX1). Using chromatin immunoprecipitation assays, we subsequently confirmed that phosphorylated YBX1 transcriptionally activates PAK4, identifying PAK4 as a downstream effector of the MASTL pathway. Moreover, mass spectrometry and phosphorylation analysis indicated that serine/threonine protein kinase 24 (STK24), a stress-responsive kinase, can activate MASTL in HCC under lenvatinib exposure. Notably, disruption of the MASTL/YBX1/PAK4 signaling axis restored HCC sensitivity to lenvatinib. Conclusions: We propose that the MASTL/YBX1/PAK4 axis, which is activated by stress-induced STK24, plays a crucial role in lenvatinib resistance. Inhibiting this axis by targeting MASTL effectively overcomes lenvatinib resistance in HCC.Keywords
This publication has 39 references indexed in Scilit:
- Precision treatment in advanced hepatocellular carcinomaCancer Cell, 2024
- MASTL: A novel therapeutic target for Cancer MalignancyCancer Medicine, 2020
- Intratumor Heterogeneity: The Rosetta Stone of Therapy ResistanceCancer Cell, 2020
- Lenvatinib: A Review in Hepatocellular CarcinomaDrugs, 2019
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 2018
- Transcriptional activation of NANOG by YBX1 promotes lung cancer stem-like properties and metastasisBiochemical and Biophysical Research Communications, 2017
- YB‐1 protein: functions and regulationWIREs RNA, 2013
- Optimizing the transient transfection process of HEK-293 suspension cells for protein production by nucleotide ratio monitoringCytotechnology, 2013
- Targeting p90 Ribosomal S6 Kinase Eliminates Tumor-Initiating Cells by Inactivating Y-Box Binding Protein-1 in Triple-Negative Breast CancersStem Cells, 2012
- Mammalian Ste20-like protein kinase 3 plays a role in hypoxia-induced apoptosis of trophoblast cell line 3A-sub-EThe International Journal of Biochemistry & Cell Biology, 2011